Skip to main content
Top
Published in: Brain Tumor Pathology 3/2022

21-03-2022 | Lymphoma | Original Article

Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group

Authors: Kenichiro Asano, Yoji Yamashita, Takahiro Ono, Manabu Natsumeda, Takaaki Beppu, Kenichiro Matsuda, Masahiro Ichikawa, Masayuki Kanamori, Masashi Matsuzaka, Akira Kurose, Toshio Fumoto, Kiyoshi Saito, Yukihiko Sonoda, Kuniaki Ogasawara, Yukihiko Fujii, Hiroaki Shimizu, Hiroki Ohkuma, Chifumi Kitanaka, Takamasa Kayama, Teiji Tominaga

Published in: Brain Tumor Pathology | Issue 3/2022

Login to get access

Abstract

Clinicopathological risk factors for a poor prognosis were investigated in elderly patients with malignant lymphoma of the central nervous system. A total of 82 pathologically confirmed, CD20-positive, diffuse large B-cell lymphoma patients aged 71 years or older who underwent therapeutic intervention in the Tohoku and Niigata area in Japan were retrospectively reviewed. A univariate analysis was performed by the log-rank test using the Kaplan–Meier method. A Cox proportional hazards model was used for multivariate analysis of risk factors. Of the 82 patients, 39 were male and 43 were female, and their median age at onset was 75 years. At the end of the study, there were 34 relapse-free patients (41.5%), 48 relapse cases (58.5%), median progression-free survival was 18 months, and median overall survival (OS) was 26 months; there were 41 deaths and 41 survivors. Multivariate analysis of median OS showed that Karnofsky Performance Status less than 60% 3 months after treatment (p = 0.022, hazard ratio (HR) = 2.591) was the clinical risk factor, and double expressor lymphoma (p = 0.004, HR = 3.163), expression of programmed death-ligand 1 in tumor infiltrating lymphocytes or tumor-associated macrophages (p < 0.001, HR = 5.455), and Epstein–Barr virus infection (p = 0.031, HR = 5.304) were the pathological risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Corn BW, Marcus SM, Topham A et al (1997) Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 79:2409–2413PubMedCrossRef Corn BW, Marcus SM, Topham A et al (1997) Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer 79:2409–2413PubMedCrossRef
2.
go back to reference Daras M, DeAngelis LM (2013) Management of elderly patients with primary central nervous system lymphoma. Curr Neurol Neurosci Rep 13:344PubMedCrossRef Daras M, DeAngelis LM (2013) Management of elderly patients with primary central nervous system lymphoma. Curr Neurol Neurosci Rep 13:344PubMedCrossRef
3.
go back to reference Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272PubMedCrossRef Ferreri AJ, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272PubMedCrossRef
4.
go back to reference Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5715PubMedCrossRef Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5715PubMedCrossRef
5.
go back to reference Tateishi K, Miyake Y, Nakamura T et al (2021) Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development. Brain Tumor Pathol 38:173–182PubMedCrossRef Tateishi K, Miyake Y, Nakamura T et al (2021) Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development. Brain Tumor Pathol 38:173–182PubMedCrossRef
6.
go back to reference Camilleri-Broet S, Criniere E, Broet P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196PubMedCrossRef Camilleri-Broet S, Criniere E, Broet P et al (2006) A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196PubMedCrossRef
8.
go back to reference Marcus C, Maragkos GA, Alterman RL et al (2021) GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas. J Clin Neurosci 83:49–55PubMedCrossRef Marcus C, Maragkos GA, Alterman RL et al (2021) GCB-type is a favorable prognostic factor in primary CNS diffuse large B-cell lymphomas. J Clin Neurosci 83:49–55PubMedCrossRef
9.
go back to reference Hatzl S, Posch F, Deutsch A et al (2020) Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematol Oncol 38:277–283PubMedPubMedCentralCrossRef Hatzl S, Posch F, Deutsch A et al (2020) Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma. Hematol Oncol 38:277–283PubMedPubMedCentralCrossRef
10.
go back to reference Furuse M, Kuwabara H, Ikeda N et al (2020) PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer 20:277PubMedPubMedCentralCrossRef Furuse M, Kuwabara H, Ikeda N et al (2020) PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer 20:277PubMedPubMedCentralCrossRef
11.
go back to reference Cho H, Kim SH, Kim SJ et al (2017) Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. Oncotarget 8:87317–87328PubMedPubMedCentralCrossRef Cho H, Kim SH, Kim SJ et al (2017) Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. Oncotarget 8:87317–87328PubMedPubMedCentralCrossRef
12.
go back to reference Hayano A, Komohara Y, Takashima Y et al (2017) Programmed cell death ligand 1 expression in primary central nervous system lymphomas: a clinicopathological study. Anticancer Res 37:5655–5666PubMed Hayano A, Komohara Y, Takashima Y et al (2017) Programmed cell death ligand 1 expression in primary central nervous system lymphomas: a clinicopathological study. Anticancer Res 37:5655–5666PubMed
13.
go back to reference Cho I, Lee H, Yoon SE et al (2020) Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer 20:120PubMedPubMedCentralCrossRef Cho I, Lee H, Yoon SE et al (2020) Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer 20:120PubMedPubMedCentralCrossRef
14.
go back to reference Takashima Y, Kawaguchi A, Sato R et al (2019) Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Sci Rep 9:10004PubMedPubMedCentralCrossRef Takashima Y, Kawaguchi A, Sato R et al (2019) Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL. Sci Rep 9:10004PubMedPubMedCentralCrossRef
15.
go back to reference Berghoff AS, Ricken G, Widhalm G et al (2014) PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 33:42–49PubMedCrossRef Berghoff AS, Ricken G, Widhalm G et al (2014) PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 33:42–49PubMedCrossRef
16.
go back to reference Sasayama T, Tanaka K, Mizowaki T et al (2016) Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in primary central nervous system lymphoma (PCNSL). Brain Pathol 26:479–487PubMedCrossRef Sasayama T, Tanaka K, Mizowaki T et al (2016) Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in primary central nervous system lymphoma (PCNSL). Brain Pathol 26:479–487PubMedCrossRef
17.
go back to reference Komohara Y, Horlad H, Ohnishi K et al (2011) M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 51:93–99PubMedCrossRef Komohara Y, Horlad H, Ohnishi K et al (2011) M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 51:93–99PubMedCrossRef
18.
go back to reference Marcelis L, Antoranz A, Delsupehe AM et al (2020) In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother 69:1751–1766PubMedCrossRef Marcelis L, Antoranz A, Delsupehe AM et al (2020) In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother 69:1751–1766PubMedCrossRef
19.
go back to reference Jamal SE, Li S, Bajaj R et al (2014) Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases. Brain Tumor Pathol 31:265–273PubMedCrossRef Jamal SE, Li S, Bajaj R et al (2014) Primary central nervous system Epstein–Barr virus-positive diffuse large B-cell lymphoma of the elderly: a clinicopathologic study of five cases. Brain Tumor Pathol 31:265–273PubMedCrossRef
20.
go back to reference Sugita Y, Terasaki M, Niino D et al (2010) Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing. J Neurooncol 100:271–279PubMedCrossRef Sugita Y, Terasaki M, Niino D et al (2010) Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing. J Neurooncol 100:271–279PubMedCrossRef
21.
go back to reference Kitai R, Matsuda K, Adachi E et al (2010) Epstein–Barr virus-associated primary central nervous system lymphoma in the Japanese population. Neurol Med Chir (Tokyo) 50:114–118CrossRef Kitai R, Matsuda K, Adachi E et al (2010) Epstein–Barr virus-associated primary central nervous system lymphoma in the Japanese population. Neurol Med Chir (Tokyo) 50:114–118CrossRef
22.
go back to reference Asano K, Yamashita Y, Ono T et al (2021) The real-world status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group. Int J Clin Oncol 27:77–94PubMedCrossRef Asano K, Yamashita Y, Ono T et al (2021) The real-world status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group. Int J Clin Oncol 27:77–94PubMedCrossRef
23.
go back to reference Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287PubMedPubMedCentralCrossRef Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275–287PubMedPubMedCentralCrossRef
24.
go back to reference Chow LQM, Haddad R, Gupta S et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845PubMedPubMedCentralCrossRef Chow LQM, Haddad R, Gupta S et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845PubMedPubMedCentralCrossRef
25.
go back to reference Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268–3277PubMedPubMedCentralCrossRef Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116:3268–3277PubMedPubMedCentralCrossRef
26.
go back to reference Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282PubMedCrossRef Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282PubMedCrossRef
27.
go back to reference Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460–3467PubMedCrossRef Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460–3467PubMedCrossRef
28.
go back to reference Matsubara T, Takada K, Azuma K et al (2019) A Clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol 26:1925–1933PubMedCrossRef Matsubara T, Takada K, Azuma K et al (2019) A Clinicopathological and prognostic analysis of PD-L2 expression in surgically resected primary lung squamous cell carcinoma. Ann Surg Oncol 26:1925–1933PubMedCrossRef
29.
go back to reference Tomita S, Kikuti YY, Carreras J et al (2015) Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol 28:1286–1296PubMedCrossRef Tomita S, Kikuti YY, Carreras J et al (2015) Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol 28:1286–1296PubMedCrossRef
30.
go back to reference Hu S, Xu-Monette ZY, Tzankov A et al (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021–4031 (quiz 4250)PubMedPubMedCentralCrossRef Hu S, Xu-Monette ZY, Tzankov A et al (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121:4021–4031 (quiz 4250)PubMedPubMedCentralCrossRef
31.
go back to reference Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043PubMedCrossRef Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043PubMedCrossRef
33.
go back to reference Kluin PMDM, Ferry JA (2008) Primary diffuse large B-cell lymphoma of the CNS. IARC Press, Lyon Kluin PMDM, Ferry JA (2008) Primary diffuse large B-cell lymphoma of the CNS. IARC Press, Lyon
34.
go back to reference Shiozawa E, Yamochi-Onizuka T, Takimoto M et al (2007) The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 31:1579–1583PubMedCrossRef Shiozawa E, Yamochi-Onizuka T, Takimoto M et al (2007) The GCB subtype of diffuse large B-cell lymphoma is less frequent in Asian countries. Leuk Res 31:1579–1583PubMedCrossRef
35.
go back to reference Phang KC, Hussin NH, Abdul RF et al (2019) Characterisation of immunogenotypes of diffuse large B-cell lymphoma. Malays J Pathol 41:101–124PubMed Phang KC, Hussin NH, Abdul RF et al (2019) Characterisation of immunogenotypes of diffuse large B-cell lymphoma. Malays J Pathol 41:101–124PubMed
36.
go back to reference Umemura H, Homma M, Shiozwa E et al (2012) Immunohistochemical analysis of the cell cycle-associated proteins in diffuse large B-cell lymphoma. Showa IKaishi 72:108–117 Umemura H, Homma M, Shiozwa E et al (2012) Immunohistochemical analysis of the cell cycle-associated proteins in diffuse large B-cell lymphoma. Showa IKaishi 72:108–117
37.
go back to reference Seki R, Ohshima K, Fujisaki T et al (2009) Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 100:1842–1847PubMedCrossRef Seki R, Ohshima K, Fujisaki T et al (2009) Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 100:1842–1847PubMedCrossRef
38.
go back to reference Radotra BD, Parkhi M, Chatterjee D et al (2020) Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: experience from a Tertiary Center in North India. Surg Neurol Int 11:424PubMedPubMedCentralCrossRef Radotra BD, Parkhi M, Chatterjee D et al (2020) Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: experience from a Tertiary Center in North India. Surg Neurol Int 11:424PubMedPubMedCentralCrossRef
39.
40.
go back to reference Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124:4622–4632PubMedCrossRef Riedell PA, Smith SM (2018) Double hit and double expressors in lymphoma: definition and treatment. Cancer 124:4622–4632PubMedCrossRef
41.
go back to reference Ma Z, Niu J, Cao Y et al (2020) Clinical significance of “double-hit” and “double-expression” lymphomas. J Clin Pathol 73:126–138PubMedCrossRef Ma Z, Niu J, Cao Y et al (2020) Clinical significance of “double-hit” and “double-expression” lymphomas. J Clin Pathol 73:126–138PubMedCrossRef
42.
go back to reference Xu-Monette ZY, Xiao M, Au Q et al (2019) Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res 7:644–657PubMedCrossRef Xu-Monette ZY, Xiao M, Au Q et al (2019) Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL. Cancer Immunol Res 7:644–657PubMedCrossRef
43.
go back to reference Godfrey J, Tumuluru S, Bao R et al (2019) PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood 133:2279–2290PubMedPubMedCentralCrossRef Godfrey J, Tumuluru S, Bao R et al (2019) PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood 133:2279–2290PubMedPubMedCentralCrossRef
45.
go back to reference Zhao T, Li C, Wu Y et al (2017) Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS ONE 12:e0176822PubMedPubMedCentralCrossRef Zhao T, Li C, Wu Y et al (2017) Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: a meta-analysis. PLoS ONE 12:e0176822PubMedPubMedCentralCrossRef
46.
go back to reference Marchesi F, Cirillo M, Bianchi A et al (2015) High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 33:110–112PubMedCrossRef Marchesi F, Cirillo M, Bianchi A et al (2015) High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol 33:110–112PubMedCrossRef
47.
go back to reference Kamada T, Togashi Y, Tay C et al (2019) PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA 116:9999–10008PubMedPubMedCentralCrossRef Kamada T, Togashi Y, Tay C et al (2019) PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci USA 116:9999–10008PubMedPubMedCentralCrossRef
48.
go back to reference Kumagai S, Togashi Y, Kamada T et al (2020) The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21:1346–1358PubMedCrossRef Kumagai S, Togashi Y, Kamada T et al (2020) The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 21:1346–1358PubMedCrossRef
49.
go back to reference Oyama T, Ichimura K, Suzuki R et al (2003) Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16–26PubMedCrossRef Oyama T, Ichimura K, Suzuki R et al (2003) Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16–26PubMedCrossRef
Metadata
Title
Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group
Authors
Kenichiro Asano
Yoji Yamashita
Takahiro Ono
Manabu Natsumeda
Takaaki Beppu
Kenichiro Matsuda
Masahiro Ichikawa
Masayuki Kanamori
Masashi Matsuzaka
Akira Kurose
Toshio Fumoto
Kiyoshi Saito
Yukihiko Sonoda
Kuniaki Ogasawara
Yukihiko Fujii
Hiroaki Shimizu
Hiroki Ohkuma
Chifumi Kitanaka
Takamasa Kayama
Teiji Tominaga
Publication date
21-03-2022
Publisher
Springer Nature Singapore
Published in
Brain Tumor Pathology / Issue 3/2022
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-022-00427-4

Other articles of this Issue 3/2022

Brain Tumor Pathology 3/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine